Amneal Spreads Bets On Generics Amid Focus On High-Barrier Opportunities
Generics Growth Supports Overall Increase In Q1 As Specialty Segment Falters
Amneal highlighted the benefits of a broad spread of generics and an increased shift towards complex products with high barriers to entry, as it reported generics sales growth in Q1 despite a tough operating environment for US generics.
You may also be interested in...
Despite a couple of setbacks during Q2, Amneal has sustained continual growth across its business, particularly in the injectables space.
Amneal says an $83.5m deal to acquire Saol Therapeutics’ baclofen franchise will also bring the firm an “experienced institutional commercial team” that will be able to support three biosimilar launches that the company now expects to execute in 2022.
Less than six months into life as an independent company, former Perrigo Rx unit Padagis has realized its second generic launch, with the first-to-market entry of generic Zomig (zolmitriptan) nasal spray.